Patent application number | Description | Published |
20100267136 | FABRICATION OF VASCULARIZED TISSUE USING MICROFABRICATED TWO-DIMENSIONAL MOLDS - Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and/or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided. | 10-21-2010 |
20140234953 | FABRICATION OF VASCULARIZED TISSUE USING MICROFABRICATED TWO-DIMENSIONAL MOLDS - Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and/or thick, structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided. | 08-21-2014 |
Patent application number | Description | Published |
20100240051 | Device and Method for Preparing and Performing Multiple Polymerase Chain Reactions - The present invention relates to methods, kits and devices with multiple open reaction chambers having multiple pre-deposited primer compositions, and a basic sample loading mechanism that utilizes an immiscible companion fluid for preparing and performing multiple Polymerase Chain Reactions | 09-23-2010 |
20120135874 | SINGLE MOLECULE SPECTROSCOPY FOR ANALYSIS OF CELL-FREE NUCLEIC ACID BIOMARKERS - The present invention relates, e.g., to a method for detecting a nucleic acid molecule of interest in a sample comprising cell-free nucleic acids, comprising fluorescently labeling the nucleic acid molecule of interest, by specifically binding a fluorescently labeled nanosensor or probe to the nucleic acid of interest, or by enzymatically incorporating a fluorescent probe or dye into the nucleic acid of interest, illuminating the fluorescently labeled nucleic acid molecule, causing it to emit fluorescent light, and measuring the level of fluorescence by single molecule spectroscopy, wherein the detection of a fluorescent signal is indicative of the presence of the nucleic acid of interest in the sample. | 05-31-2012 |
20130303394 | FLUIDIC CHIPS HAVING SURFACE ENERGY TRAPS - A method of using a fluidic device includes providing a fluidic chip having a plurality of surface energy traps; depositing at least one fluid droplet on the fluidic chip, the fluid droplet including magnetic particles suspended therein; and moving at least a portion of the at least one fluid droplet across a surface of the fluidic chip by altering a magnetic interaction applied to the magnetic particles such that the at least one fluid droplet interacts with at least one of the plurality of surface energy traps. | 11-14-2013 |
Patent application number | Description | Published |
20090006559 | Application Message Subscription Tracking In A High Speed, Low Latency Data Communications Environment - Methods, systems, and products are disclosed for application message subscription tracking in a high speed, low latency data communications environment that includes: receiving, by a stream administration server from a subscribing client device, a subscription initiation request, the subscription initiation request specifying a message topic, the message topic specifying application messages for transmission to the subscribing client device from a message transmitting device; brokering, by the stream administration server, establishment of a message stream that provides the application messages for the specified message topic from the message transmitting device to the subscribing client device; and updating, by the stream administration server, a client subscription repository for monitoring application message subscriptions in dependence upon the subscription initiation request. | 01-01-2009 |
20090006560 | Terminating An Application Message Subscription - Methods, systems, and products are disclosed for terminating an application message subscription that include: receiving, by messaging middleware of a subscribing client device, application messages having one or more message topics on one or more message streams from one or more message transmitting devices; receiving, by the messaging middleware from a stream administration server, a subscription termination message specifying a particular message topic for application messages that the subscription client device is no longer authorized to receive; and ceasing, by the messaging middleware, to provide the received application messages having the particular message topic to an application on the subscribing client device, including providing the received application messages having other message topics to the application. | 01-01-2009 |
Patent application number | Description | Published |
20090117154 | SYNTHETIC POLYVALENT CARBOHYDRATES AS COMPONENTS OF MICROBICIDES - Inhibitors that block the DC-SIGN mediated transmission of the HIV-virus from mucosal infection sites to T-lymphocytes. In one embodiment, the inhibitors include at least one oligosaccharide chain attached to a scaffolding framework in which the number of the oligosaccharide chains attached to the scaffold can be 2, 3, 4 or more. In another embodiment, HIV-I viral infection is treated by administration of a composition including a therapeutically effective amount of an oligosaccharide cluster and/or oligosaccharide/protein cluster binding DC-SIGN, to inhibit DC-SIGN from binding to HIV envelope glycoprotein. | 05-07-2009 |
20100173323 | GLYCOSYLATION ENGINEERED ANTIBODY THERAPY - The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody. | 07-08-2010 |
20100221241 | CONSTRAINED HIV ENVELOPE-BASED IMMUNOGEN THAT SIMULTANEOUSLY PRESENTS RECEPTOR AND CORECEPTOR BINDING SITES - The present invention relates to a soluble binding complex comprising a soluble gp120 trimer, in which only two gp120 protomers have CD4 binding sites occupied by interconnecting CD4 mimetic moieties, thereby allowing for the exposure of CD4-induced epitopes on the mimetic-bound protomers and an unoccupied CD4 binding site on the third gp120 protomer. | 09-02-2010 |
20110070607 | GLYCOPROTEIN SYNTHESIS AND REMODELING BY ENZYMATIC TRANSGLYCOSYLATION - A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery. | 03-24-2011 |
20120226024 | CORE FUCOSYLATED GLYCOPEPTIDES AND GLYCOPROTEINS: CHEMOENZYMATIC SYNTHESIS AND USES THEREOF - A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described. | 09-06-2012 |
20130131325 | GLYCOPROTEIN SYNTHESIS AND REMODELING BY ENZYMATIC TRANSGLYCOSYLATION - A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery. | 05-23-2013 |
20130137857 | TRANSGLYCOSYLATION ACTIVITY OF GLYCOSYNTHASE MUTANTS OF AN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE (ENDO-D) FROM STREPTOCOCCUS PNEUMONIAE - The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain. | 05-30-2013 |
20140348865 | IMMUNOGENS BASED ON AN HIV-1 V1V2 SITE-OF-VULNERABILITY - Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject. | 11-27-2014 |
20150087811 | GLYCOPROTEIN SYNTHESIS AND REMODELING BY ENZYMATIC TRANSGLYCOSYLATION - A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery. | 03-26-2015 |
20150087814 | CHEMOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS THEREOF - The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgGl-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans. | 03-26-2015 |
Patent application number | Description | Published |
20090246792 | METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIATIONS - The invention employs an unlabeled signal primer comprising a 5′ adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3′ end of which hybridizes to the complement of the 5′ adapter sequence of the signal primer to produce a 5′ overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5′ overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target. | 10-01-2009 |
20110105350 | DIAGNOSIS OF SEPSIS - Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set. | 05-05-2011 |
20140141435 | DIAGNOSIS OF SEPSIS - Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set. | 05-22-2014 |
Patent application number | Description | Published |
20080286758 | REAGENTS AND KITS FOR DETECTION OF INFLUENZA VIRUS AND THE LIKE - The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase. | 11-20-2008 |
20110031322 | Novel air regulation device and air conditioning system - A multiple zone HVAC system comprises powered flow rate adjustable registers. It can further comprise zone controllers that can wirelessly control the registers, and a central controller that controls the HVAC unit and coordinates zone controllers. | 02-10-2011 |
20110097753 | Chemiluminescent methods and reagents for analyte detection - The present invention relates to chemiluminescent method and regent to detect analyte. One aspect of the current invention relates to using enzyme substrate that can be cleaved by target enzyme to release chemiluminescent compound giving light signal for the detection of varieties of target enzymes. Another aspect of the current invention relates to use chemiluminescent enzyme coupled with analyte binding molecules to detect specific analyte molecules in a homogenous phase. | 04-28-2011 |
20110189655 | REAGENTS AND KITS FOR DETECTION OF INFLUENZA VIRUS AND THE LIKE - The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase. | 08-04-2011 |
Patent application number | Description | Published |
20100118300 | CYLINDRICAL ILLUMINATION CONFOCAL SPECTROSCOPY SYSTEM - A cylindrical illumination confocal spectroscopy system has a fluidic device having a fluid channel defined therein, an objective lens unit arranged proximate the fluidic device, an illumination system in optical communication with the objective lens unit to provide light to illuminate a sample through the objective lens unit, and a detection system in optical communication with the objective lens unit to receive at least a portion of light that passes through the objective lens unit from the sample. The illumination system includes a beam-shaping lens unit constructed and arranged to provide a substantially planar illumination beam that subtends across, and is longer than, a lateral dimension of the fluid channel, the substantially planar illumination beam having a diffraction limited thickness in a direction substantially orthogonal to the lateral dimension of the fluid channel. The substantially planar illumination beam incident upon the fluidic device has a width that is substantially longer than the lateral dimension of the fluid channel such that the substantially planar illumination beam has an illumination intensity that is uniform across the lateral dimension of the fluid channel to within ±10%. The detection system comprises an aperture stop defining a substantially rectangular aperture having a longitudinal dimension and a transverse dimension. The aperture stop is arranged so that the substantially rectangular aperture is confocal with an illuminated portion of the fluid channel such that the transverse dimension of the substantially rectangular aperture substantially subtends the lateral dimension of the fluid channel without extending substantially beyond the fluid channel and allows light to pass from only a uniform excitation region while occluding light from outside the uniform excitation region, and the lateral dimension of the substantially rectangular aperture substantially matches the diffraction limited thickness of the planar illumination beam. | 05-13-2010 |
20110165565 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE EXTRACTION AND METHYLATION DETECTION - The present invention features methods and compositions for methylation detection, as well as a novel method for polynucleotide extraction and sodium bisulfite treatment. | 07-07-2011 |
20110171741 | DNA INTEGRITY ASSAY (DIA) FOR CANCER DIAGNOSTICS, USING CONFOCAL FLUORESCENCE SPECTROSCOPY - The present invention relates, e.g., to a method for determining the size distribution of DNA molecules in a sample comprising cell-free nucleic acid, comprising labeling the DNA with a fluorescent dye in a stoichiometric manner, subjecting the DNA to molecular spectroscopy (e.g., cylindrical illumination confocal spectroscopy), analyzing suitable fluorescent burst parameters of the labeled DNA, and conducting single molecule DNA integrity analysis of the labeled DNA molecules in the sample. In one embodiment of the invention, the method is used as a diagnostic method for detecting cancer. | 07-14-2011 |
20130096035 | SELF-SUSTAINED FLUIDIC DROPLET CASSETTE AND SYSTEM FOR BIOCHEMICAL ASSAYS - A fluidic cartridge for biochemical assays includes a cartridge body defining a first droplet region and a second droplet region with a droplet restraining barrier therebetween. The droplet restraining barrier has a gap between the first and the second droplet regions. The fluidic cartridge also includes a first droplet dispensed in the first droplet region. The first droplet includes a plurality of magnetic particles dispersed therein. The fluidic cartridge also includes a second droplet disposed in the second droplet region. The plurality of magnetic particles are sufficiently small to be drawn through the gap between the first and second droplet regions when compelled by an applied magnetic field, and the first droplet is restrained by the restraining barrier while the plurality of magnetic particles are drawn through the gap. A biochemical assay system includes a stage adapted to receive a fluidic cartridge, and a magnetic control assembly that includes a magnet. The magnet of the magnetic control assembly is movable to direct motion of magnetic particles contained within the fluidic cartridge. | 04-18-2013 |
20130165346 | SYSTEM AND METHOD FOR SCREENING A LIBRARY OF SAMPLES - A continuous throughput microfluidic system includes an input system configured to provide a sequential stream of sample plugs; a droplet generator arranged in fluid connection with the input system to receive the sequential stream of sample plugs and configured to provide an output stream of droplets; a droplet treatment system arranged in fluid connection with the droplet generator to receive the output stream of droplets in a sequential order and configured to provide a stream of treated droplets in the sequential order; a detection system arranged to obtain detection signals from the treated droplets in the sequential order; a control system configured to communicate with the input system, the droplet generator, and the droplet treatment system; and a data processing and storage system configured to communicate with the control system and the detection system. | 06-27-2013 |
20130183246 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT MICROFLUIDIC BEAD PRODUCTION - A system for producing microbeads includes a microfluidic device defining a supply channel and a shearing channel, a microbead precursor material disposed in the supply channel, a carrier fluid disposed in the shearing channel, and a pressure distribution system fluidly connected to each of the supply channel and the shearing channel to control at least relative pressures of the microbead precursor material and the carrier fluid. The supply channel includes a check valve adapted to be subjected to a bias pressure that is sufficient to close the check valve to flow of microbead precursor material when a supply pressure of the microbead precursor material is below a threshold pressure and is open to flow of the microbead precursor material when the supply pressure of the microbead precursor material is greater than the threshold pressure. An end of the supply channel opens into the shearing channel such that the microbead precursor material is sheared into droplets by the carrier fluid flowing through the shearing channel. A pressure of the carrier fluid is less than the bias pressure. The microbead precursor material and the carrier fluid are substantially immiscible. | 07-18-2013 |
20140206007 | ELECTROMAGNETICALLY ACTUATED DROPLET MICROFLUIDIC CHIP AND SYSTEM - A microfluidic system includes a microfluidic cartridge and an electromagnetic droplet actuator arranged proximate the microfluidic cartridge. The microfluidic cartridge includes a plurality of droplet wells with topological barrier structures between adjacent wells. The topological barrier structures are configured to allow magnetic particles and material attached to the magnetic particles to pass between adjacent wells while confining droplets within respective wells. The electromagnetic droplet actuator includes a plurality of electromagnetic components arranged to provide an electronically selectable magnetic field pattern to actuate movement of a plurality of magnetic particles when contained within at least one droplet in at least one of the plurality of droplet wells. | 07-24-2014 |
20150031573 | MIRNA ANALYSIS METHODS - The present invention provides a PCR-free, multiplexed ligation assay for miRNA expression analysis that produces highly quantitative, 10-100 plex miRNA profiling in a single reaction. The inventive methods use a 2-step ligation assay to generate an array of miRNA specific ligation products that can be decoded and quantified by a size discrimination method such as gel electrophoresis or single molecule separation. One embodiment is a low-cost assay that can be performed using standard tools available in nearly all molecular biology laboratories. This assay requires nothing more than a gel apparatus and reader for detection. Other embodiments include use of magnetic beads and other size exclusion apparatus which give increasingly higher sensitivity, lower sample consumption, and reduced processing steps. | 01-29-2015 |
20150037802 | FABRICATION OF HIERARCHICAL SILICA NANOMEMBRANES AND USES THEREOF FOR SOLID PHASE EXTRACTION OF NUCLEIC ACIDS - The present invention provides a novel method to fabricate silica nanostructures on thin polymer films based on silica deposition and self-wrinkling induced by thermal shrinkage. These micro- and nano-scale structures have vastly enlarged the specific area of silica, thus the silica nanomembranes can be used for solid phase extraction of nucleic acids. The inventive silica nanomembranes are suitable for nucleic acid purification and isolation and demonstrated better performance than commercial particles in terms of DNA recovery yield and integrity. In addition, the silica nanomembranes have extremely high nucleic acid capacity due to its significantly enlarged specific surface area of silica. Methods of use and devices comprising the silica nanomembranes are also provided. | 02-05-2015 |
Patent application number | Description | Published |
20120213794 | AX213 AND AX132 PSCK9 ANTAGONISTS AND VARIANTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 08-23-2012 |
20120231005 | AX1 AND AX189 PSCK9 ANTAGONISTS AND VARIANTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 09-13-2012 |
20140121123 | METHODS FOR DIVERSIFYING ANTIBODIES, ANTIBODIES DERIVED THEREFROM AND USES THEREOF - The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided. A method of producing diverse antibodies comprising amino acid substitutions in one of the CDR region and the FW region comprising 3 contiguous FW sequence amino acids adjacent to each CDR on either side is described herein. The substitutions are relative to database or germline sequences. Not all substitution are preserved in conservative regions. | 05-01-2014 |
Patent application number | Description | Published |
20090136524 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD. | 05-28-2009 |
20090258789 | METHODS OF DETERMINING THE PROGNOSIS OF AN ADENOCARCINOMA - Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed. | 10-15-2009 |
20100197770 | Methods for Determining Heptocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells - The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells. | 08-05-2010 |
20100322950 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD. | 12-23-2010 |
20110206703 | GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins. | 08-25-2011 |
20120294870 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD. | 11-22-2012 |
20140018409 | Method for Determining Hepatocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells - Described herein are methods of determining an HCC subtype in a subject which includes a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. Also described are methods of detecting HCC stem cells in a sample, and methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells. | 01-16-2014 |
20140220043 | GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described. | 08-07-2014 |
Patent application number | Description | Published |
20100112644 | Methods for detection and quantitation of small RNAs - Improved methods that increase the specificity and sensitivity of detection of small RNAs, including miRNAs, using oligonucleotide primers and nucleic acid amplification, are provided. Reaction conditions that result in preferential decrease in cDNA synthesis of RNAs other than the small RNA molecules targeted for detection during miRNA tailing and reverse transcription reactions are described. Using these reaction conditions greater sensitivity and specificity of amplification of small RNAs including miRNAs is achieved. | 05-06-2010 |
20120178078 | Methods and Compositions for Nucleic Acid Detection - The present application relates to Multicomponent Nucleic Acid Enzymes (MNAzymes), which may be used for detecting, identifying and/or quantifying targets. More particularly, this application provides methods of designing and making more reliable MNAzymes, as well as compositions comprising MNAzyme components and methods of using MNAzymes. | 07-12-2012 |
20120252689 | GENE EXPRESSION SIGNATURE FOR WNT/B-CATENIN SIGNALING PATHWAY AND USE THEREOF - The present invention relates to a novel set of 16 biomarkers, microarrays that provide for the detection thereof, an expression signature comprising 16 genes or a subset thereof, and the use thereof in determining the regulation status of Wnt/β-catenin signaling pathway. The regulation status of Wnt/β-catenin signaling pathway may be assayed based on the level of expression of one or more of these genes. The expression of these biomarkers may be used to evaluate Wnt/β-catenin pathway deregulation status; classify a cell sample as having a deregulated or regulated Wnt/β-catenin signaling pathway; determine whether an agent modulates the Wnt/β-catenin signaling pathway; predict response of a subject to an agent that modulates the Wnt/β-catenin signaling pathway; assign treatment to a subject; or evaluate the pharmacodynamic effects of therapies designed to regulate Wnt/β-catenin pathway signaling. | 10-04-2012 |
20130122511 | METHODS FOR DETECTION AND QUANTITATION OF SMALL RNAs - Improved methods that increase the specificity and sensitivity of detection of small RNAs, including miRNAs, using oligonucleotide primers and nucleic acid amplification, are provided. Reaction conditions that result in preferential decrease in cDNA synthesis of RNAs other than the small RNA molecules targeted for detection during miRNA tailing and reverse transcription reactions are described. Using these reaction conditions greater sensitivity and specificity of amplification of small RNAs including miRNAs is achieved. | 05-16-2013 |
20140274734 | DNA QUALITY CONTROLS - The present disclosure provides methods, arrays and kits for assessing the quality of genomic DNA samples, especially those obtained from formalin-fixed paraffin-embedded (FFPE) samples. The methods, arrays and kits provided herein use primer pairs specific to regions in the genomes of the organisms from which genomic DNA samples are obtained that have identical or nearly identical copies distributed across multiple chromosomes. | 09-18-2014 |
Patent application number | Description | Published |
20120088845 | Synthesis, capping and dispersion of nanocrystals - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 04-12-2012 |
20130207053 | SYNTHESIS, CAPPING AND DISPERSION OF NANOCRYSTALS - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 08-15-2013 |
20130221279 | SYNTHESIS, CAPPING AND DISPERSION OF NANOCRYSTALS - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 08-29-2013 |
20140045323 | SYNTHESIS, CAPPING AND DISPERSION OF NANOCRYSTALS - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 02-13-2014 |
20140295649 | SYNTHESIS, CAPPING AND DISPERSION OF NANOCRYSTALS - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 10-02-2014 |
20140302664 | SYNTHESIS, CAPPING AND DISPERSION OF NANOCRYSTALS - Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films. | 10-09-2014 |
Patent application number | Description | Published |
20120121718 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION - The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues. | 05-17-2012 |
20130236556 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION - The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues. | 09-12-2013 |
Patent application number | Description | Published |
20090150735 | METADATA BROKERING SERVER AND METHODS - Exemplary embodiments of the present invention provide methods and systems for supplying rich multimedia metadata usable to generate, e.g., sophisticated entertainment user interfaces in the home. These methods and systems can be implemented as a server-based software application that feeds multiple, diverse clients. The server functionality could be distributed, even co-located physically with one or more clients, or centralized. The server aggregates, filters, validates, augments and links metadata from disparate sources. The server transforms the metadata into a more manageable and extensible internal format. The server communicates with client devices using a schema-independent protocol, providing metadata in the appropriate format that suites the clients needs. | 06-11-2009 |
20120185492 | Metadata Brokering Server and Methods - Exemplary embodiments of the present invention provide methods and systems for supplying rich multimedia metadata usable to generate, e.g., sophisticated entertainment user interfaces in the home. These methods and systems can be implemented as a server-based software application that feeds multiple, diverse clients. The server functionality could be distributed, even co-located physically with one or more clients, or centralized. The server aggregates, filters, validates, augments and links metadata from disparate sources. The server transforms the metadata into a more manageable and extensible internal format. The server communicates with client devices using a schema-independent protocol, providing metadata in the appropriate format that suites the clients needs. | 07-19-2012 |
20130291009 | Metadata Brokering Server and Methods - Exemplary embodiments of the present invention provide methods and systems for supplying rich multimedia metadata usable to generate, e.g., sophisticated entertainment user interfaces in the home. These methods and systems can be implemented as a server-based software application that feeds multiple, diverse clients. The server functionality could be distributed, even co-located physically with one or more clients, or centralized. The server aggregates, filters, validates, augments and links metadata from disparate sources. The server transforms the metadata into a more manageable and extensible internal format. The server communicates with client devices using a schema-independent protocol, providing metadata in the appropriate format that suites the clients needs. | 10-31-2013 |
Patent application number | Description | Published |
20130072669 | Covalently Functionalized Carbon Nanostructures and Methods for Their Separation - The present invention is directed to carbon nanostructures, e.g., carbon nanotubes, methods of covalently functionalizing carbon nanostructures, and methods of separating and isolating covalently functionalized carbon. In some embodiments, carbon nanotubes are reacted with alkylating agents to provide water soluble covalently functionalized carbon nanotubes. In other embodiments, carbon nanotubes are reacted with a thermally-responsive agent and exposed to light in order to separate carbon nanotubes of a specific chirality from a mixture of carbon nanotubes. | 03-21-2013 |
20130306870 | CARBON NANOTUBE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - Carbon nanotube compositions suitable for printing, methods of making carbon nanotube compositions, and substrates having a print thereon containing carbon nanotube compositions, and uses thereof. The carbon nanotubes of the compositions are individualized. The carbon nanotube compositions can be used in applications, such as document security. | 11-21-2013 |
20140342949 | Tube-in-a-Tube Electronic Sensors - The present invention is directed to tube-in-a-tube electronic materials and electronic chemical sensors comprising tube-in-a-tube configurations such as covalently functionalized double-walled carbon nanotubes. | 11-20-2014 |
Patent application number | Description | Published |
20090325816 | Massively parallel lithography with two-dimensional pen arrays - Massive parallel printing of structures and nanostructures, including lipids, at high speed with high resolution and high quality using two dimensional arrays comprising cantilevers and tip-based transfer of material to a surface. The array is designed so only tips touch the surface. This can be accomplished by long tips and bent cantilevers and alignment. An article comprising: a two-dimensional array of a plurality of cantilevers, wherein the array comprises a plurality of base rows, each base row comprising a plurality of cantilevers, wherein each of the cantilevers comprise tips at the cantilever end away from the base, wherein the number of cantilevers is greater than 250, and wherein the tips have an apex height relative to the cantilever of at least four microns, and a support for the array. Combinatorial arrays and bioarrays can be prepared. The arrays can be manufactured by micromachining methods. | 12-31-2009 |
20100071098 | SCANNING PROBE EPITAXY - A dual tip probe for scanning probe epitaxy is disclosed. The dual tip probe includes first and second tips disposed on a cantilever arm. The first and second tips can be a reader tip and a synthesis tip, respectively. The dual tip probe further includes a rib disposed on the cantilever arm between the first and second tips. The dual tip probe can also include a strain gauge disposed along the length of the cantilever arm. | 03-18-2010 |
20100115672 | SCANNING PROBE EPITAXY - A dual tip probe for scanning probe epitaxy and a method of forming the dual tip probe are disclosed. The dual tip probe includes first and second tips disposed on a cantilever arm. The first and second tips can be a reader tip and a synthesis tip, respectively. The first tip can remain in contact with a substrate during writing and provide in situ characterization of the substrate and or structures written, while the second tip can perform in non-contact mode to write and synthesis nanostructures. This feature can allow the dual tip probe to detect errors in a printed pattern using the first tip and correct the errors using the second tip. | 05-06-2010 |
Patent application number | Description | Published |
20080286306 | HIV vaccines based on Env of multiple clades of HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 11-20-2008 |
20090175910 | Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization - Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections. | 07-09-2009 |
20090214588 | Vaccines against aids comprising cmv/r-nucleic acid constructs - The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided. | 08-27-2009 |
20100111998 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single Glade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 05-06-2010 |
20110200636 | METHOD FOR IMPROVING THE BREADTH OF THE IMMUNE RESPONSE TO DIVERSE STRAINS AND CLADES OF HIV - The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided. | 08-18-2011 |
20110274721 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 11-10-2011 |